Research for treatments, prevention and a cure
DEBUG INFO [ON]
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Vaccines and Immunotherapies (VIT)


CTN 256: Phase IIB study of efficacy and safety of AGS-004

Trial results

Print Friendly, PDF & Email

A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption

About the study

This clinical research study tested the efficacy and safety of AGS-004, an experimental immunotherapy, to control HIV replication during analytical treatment interruption. As a follow up study to CTN 229 and CTN 239, this study was designed to see if AGS-004 increases the body’s immune response to HIV and if, even after stopping ART, the immunotherapy can control HIV replication.

AGS-004 is created from a person’s own dendritic cells — white blood cells that stimulate the body’s immune system — and a sample of their HIV virus. This is the first experimental treatment designed from a person’s HIV genetic material and their body’s cells. This study was sponsored by Argos Therapeutics (Durham, NC), CIHR, and the NIH. For more information about this trial, see clinicaltrials.gov.

About the approach

In this randomized, double-blind, phase 2B trial, researchers administered AGS-004 intradermally — into the skin — every four weeks while on ART. At week sixteen, participants underwent a clinically controlled ART interruption for twelve weeks while still receiving the injection every four weeks. Any study participant with a plasma HIV level >200 copies per mL or a CD4 count >450 cells per cubic mm at week fourteen did not undergo the treatment interruption. Plasma HIV levels and CD4 counts were monitored through the treatment interruption.

Study results

The immune response caused by AGS-004 was not effective in improving viral control compared with placebo, as measured during treatment interruption. Both the plasma HIV levels and changes in CD4 cell count were similar between placebo and treatment groups. Although CTN 229 and 239 found that AGS-004 was safe and showed promising effects on the immune system, CTN 256 found that there was no antiviral effect compared to placebo.

Participating sites

Ontario
The Ottawa Hospital
Nancy Tremblay

Quebec
Montreal Chest Institute
Dr. Jean-Pierre Routy

Quartier Latin
Dr. Jean-Guy Baril

Clinique L’ Actual
Dr. Benoit Trottier

Additional Information

Principal Investigator:
Dr. Jean-Pierre Routy
McGill University

Publication:
Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, Margolis DM, Trottier B, Wood K, Nicolette C. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72(1):31-8.

 

Latest News

CTNPT 031 — The HAVARTI trial

| Uncategorized | No Comments

“Our study will test whether a licensed and commonly used medication could lead to a functional cure for HIV infection,”…

CTN at CAHR 2018

| Uncategorized | No Comments

Along with supporting CAHR as a Bronze Sponsor, the CTN is proud to host several important events throughout the week.

CTNPT 029: Group Therapy for People Living with HAND

| Uncategorized | No Comments

Approximately half of the aging HIV-positive population will be affected by HIV-Associated Neurocognitive Disorder (HAND). People with HAND can experience…

In Memoriam: Dr. David Cooper

| Uncategorized | No Comments

The CTN offers condolences to the family, friends, and colleagues of Dr. David Cooper. Dr. Cooper dedicated his life to…

Research for treatments, prevention and a cure